Navigation auf uzh.ch

Suche

Department of Adult Psychiatry and Psychotherapy

Publication

Publications (10 most important)

Holper, L., Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity. Research Synthesis Methods, 2020. 11(2): 275-286. DOI: 10.1002/jrsm.1393.

Holper, L., Conditional power of antidepressant network meta-analysis. BMC Psychiatry, 2021. 21(1): 129. DOI: 10.1186/s12888-021-03094-5.

Holper, L. and M.P. Hengartner, Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials. BMC Psychiatry, 2020. 20(1): 437. DOI: 10.1186/s12888-020-02839-y.

Holper, L., Raising Placebo Efficacy in Antidepressant Trials Across Decades Explained by Small-Study Effects: A Meta-Reanalysis. Frontiers in Psychiatry, 2020. 11. DOI: 10.3389/fpsyt.2020.00633.

Scholkmann F, Holper L, Preller KH, Vollenweider FX (2019) Effects of psilocybin on functional connectivity measured. with  fNIRS:  Insights  from  a single-subject pilot study. Sciene Matters.

Holper L (2020) Optimal doses of antidepressants in dependence on age: combined covariate actions in Bayesian network meta-analysis. EClinicalMedicine, 20:100219.

Grosskurth E, Bach DR, Holper L (2019) No substantial change in the balance between model-free and model-based control via training on the two-step task. PLOS Computational Biology, 15(11): e1007443.

Holper L, Lan MJ, Brown PJ, Burke AK, Sublette ME, Burke A, Mann JJ (2019) Brain cytochrome‐c‐oxidase as a marker of mitochondrial function: A pilot study in major depression using NIRS. Depression & Anxiety, 36, 766-779.

Holper L, Ben-Shachar D, Mann JJ (2019) Psychotropic and neurological medication effects on mitochondrial complex I and IV in rodent models, European Neuropsychopharmacology, 29(9):986-1002.

Holper L, Ben-Shachar D, Mann JJ (2019) Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease. Neuropsychopharmacology, 44(5):837-849.